Summary Background There is a need to improve therapies for osteoarthritis in horses. Objectives To assess the efficacy of equine allogeneic chondrogenic‐induced mesenchymal stem cells combined with equine allogeneic plasma as a novel therapy for osteoarthritis in horses. Study design Randomised, double‐blinded, placebo‐controlled experiment. Methods In 12 healthy horses, osteoarthritis was induced in the metacarpophalangeal joint using an osteochondral fragment‐groove model. Five weeks after surgery, horses were randomly assigned to either an intra‐articular injection with chondrogenic‐induced mesenchymal stem cells + equine allogeneic plasma (= intervention) or with 0.9% saline solution (= control). From surgery until the study end, horses underwent a weekly joint and lameness assessment. Synovial fluid was collected for cytology and biomarker analysis before surgery and at Weeks 5, 5 + 1d, 7, 9 and 11. At Week 11, horses were subjected to euthanasia, and the metacarpophalangeal joints were evaluated macroscopically and histologically. Results No serious adverse events or suspected adverse drug reactions occurred during the study. A significant improvement in visual and objective lameness was seen with the intervention compared with the control. Synovial fluid displayed a significantly higher viscosity and a significantly lower glycosaminoglycan concentration in the intervention group. Other biomarkers or cytology parameters were not significantly different between the treatment groups. Significantly less wear lines and synovial hyperaemia were present in the intervention group. The amount of cartilage oligomeric matrix protein, collagen type II and glycosaminoglycans were significantly higher in the articular cartilage of the intervention group. Main limitations This study assessed the short‐term effect of the intervention on a limited number of horses, using an osteoarthritis model. This study also included multiple statistical tests, increasing the risk of type 1 error. Conclusions Equine allogeneic chondrogenic‐induced mesenchymal stem cells combined with equine allogeneic plasma may be a promising treatment for osteoarthritis in horses. The Summary is available in Spanish – see Supporting Information
The efficient and fast isolation of microorganisms from infected SF by the BACTEC system allows for rapid susceptibility testing and a more appropriate antibiotic treatment.
The medical records of 30 horses (18 Warmbloods, 7 draught horses, 3 other breeds and 2 of unknown origin) with chronic proliferative pododermatitis (canker) were reviewed and long-term outcome was obtained by telephone questionnaire. In 28/30 cases, the owner was the first to discover the problem. The disease was initially recognised as canker in only 5/28 cases, whereas in 10/28 cases a treatment for thrush had been continued for several months before referral. There was a similar prevalence in the fore (41) and hind (44) hooves; 13/30 horses had 4 hooves affected. Treatment consisted of surgical debridement and hoof care. Duration of hospitalisation was significantly decreased in horses receiving oral prednisolone for 3 weeks compared to those without this additional systemic treatment (mean +/- s.d. 24 +/- 5 days, n = 7 vs. 40 +/- 19 days, n = 19, respectively). Long-term follow-up ranged from 3 months to 6 years (36 +/- 22 months) and was available for 24 horses. No recurrence was reported in 10 horses. In 14 horses problems recurred within the first year, and 6 had been subjected to euthanasia for this reason specifically, whereas the others were managed by regular trimming. There was no significant association between recurrence and the number of affected hooves or the use of any systemic treatment. Horses with delayed referral because of preceding treatments had significantly more chance to develop recurrence, highlighting the need for prompt diagnosis and subsequent treatment
SummaryBackgroundNutraceuticals are often used in the management of equine osteoarthritis, but scientific evidence of their efficacy is lacking.ObjectivesTo study the preventive effects of two new nutraceuticals after the experimental induction of synovitis in comparison with positive and negative control treatments.Study designBlinded, controlled, randomised experiment.MethodsTwenty‐four healthy Standardbred horses were randomly allocated to supplement AT (multi‐ingredient, 28 days), supplement HP (collagen hydrolysate, 60 days), meloxicam (4 days) or placebo (60 days). Synovitis was induced in the right intercarpal joint by intra‐articular injection of 0.5 ng lipopolysaccharide (LPS) of Escherichia coli while treatments were continued. Blood and synovial fluid were sampled before treatment, immediately prior to LPS injection, and at 8, 24 and 48 h post‐injection. Synovial fluid samples were analysed for total nucleated cell count (TNCC), total protein (TP) and selected biomarkers (prostaglandin E2 [PGE 2], interleukin‐6 [IL‐6], glycosaminoglycans [GAGs], type II collagen synthesis [CPII], matrix metalloproteinase [MMP]). Lameness was scored by visual examination and pressure plate analysis immediately prior to LPS injection, and at 8, 24 and 48 h post‐injection. Clinical examinations were performed before treatment, immediately prior to LPS injection, at 2, 4 and 6 h post‐injection, and then twice per day during the test period.ResultsBefore treatment and intra‐articular challenge, there were no statistically significant differences among the treatment groups for any of the parameters. After intra‐articular challenge, the placebo group showed significantly higher synovial fluid TP, TNCC and PGE 2 compared with the meloxicam group, although the model did not induce a relevant amount of lameness. Both nutraceuticals resulted in significantly lower synovial fluid TP, TNCC and PGE 2 compared with placebo. No statistical differences in IL‐6, GAGs, CPII or MMPs were observed among treatment groups. No adverse effects were observed.Main limitationsDespite evidence of synovitis, lameness was too mild to detect.ConclusionsThe preventive administration of these nutraceuticals showed anti‐inflammatory effects in this validated synovitis model. Therefore, further studies of their clinical applicability are warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.